Zolbetuximab (200 μg, i.v.) alone and in combination with Gemcitabine (HY-17026) (50 mg/kg, i.p.) exhibits antitumor activity in mouse BxPC-3-CLDN18.2 xenograft models[2].
Zolbetuximab (5.7 mg/kg, i.p., three times per week for five weeks) inhibits tumor growth in SNU-620 cells xenograft model[3].
| Animal Model: | mouse BxPC-3-CLDN18.2, MIA PaCa-2-CLDN18.2 xenograft model[2] |
| Dosage: | 200 μg alone or with 50 mg/kg Gemcitabine |
| Administration: | i.v.; i.p. (Gemcitabine) |
| Result: | Inhibited tumor growth in two models, and prevented lung metastasis formation.
Prolonged survival time, and lowered fractions of CLDN18.2+ cells in MIA PaCa-2-CLDN18.2 xenograft. |
